[en] cis-N-(1-Benzyl-2-methylpyrrolidine-3-yl)-5-iodo-2-methoxy-4-(methylamino) benzamide (IYM), a YM-09151-2 analog iodinated at the 5-position of the benzoyl moiety, was synthesized and evaluated as a potential radiopharmaceutical for investigating brain dopamine D₂ receptors by single photon emission computer tomography (SPECT). [¹²⁵I]IYM was synthesized by a halogen exchange reaction and purified by high-performance liquid chromatography (HPLC). An in vitro competitive binding study with [³H]spiperone using rat striatal synaptosomal membranes revealed that IYM had higher affinity for dopamine D₂ receptors than did YM-09151-2 or spiperone. In a saturation binding study using rat striatal synaptosomal membranes, IYM had a K_d of 0.04 nM. Biodistribution studies in mice disclosed that [¹²⁵I]IYM exhibited high and specific striatal uptake, with the striatal/cerebellar uptake ratio being 14 at 120 min after injection. Furthermore, the striatal uptake of [¹²⁵I]IYM was saturable, and [¹²⁵I]IYM was displaced only by dopaminergic compounds. Ex vivo autoradiographic studies in rats further confirmed the high uptake and retention of this agent in the striatum and total blockade of its uptake by YM-09151-2. Thus, IYM showed specific binding to dopamine D₂ receptors in the rodent striatum and therefore holds great potential for use in in vivo dopamine D₂ receptor studies